Treakisym continues to generate double-digit sales growth, although 2018 sales were below our expectations. A temporary dip in revenue is expected in 2020 as inventory held by Eisai is wound down, ahead of SymBio establishing its own sales organization in Japan at the end of that year. The ongoing Phase III study of Treakisym in diffuse large B-cell lymphoma (DLBCL) is on track to allow a potential filing in Q220; we estimate that the DLBCL indication could double peak sales, if approved. Sym
18 Apr 2019
SymBio Pharmaceuticals - Looking forward to Treakisym Phase III data
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
SymBio Pharmaceuticals - Looking forward to Treakisym Phase III data
Symbio Pharmaceuticals Limited (4582:TKS) | 0 0 0.0%
- Published:
18 Apr 2019 -
Author:
Dr Dennis Hulme -
Pages:
13
Treakisym continues to generate double-digit sales growth, although 2018 sales were below our expectations. A temporary dip in revenue is expected in 2020 as inventory held by Eisai is wound down, ahead of SymBio establishing its own sales organization in Japan at the end of that year. The ongoing Phase III study of Treakisym in diffuse large B-cell lymphoma (DLBCL) is on track to allow a potential filing in Q220; we estimate that the DLBCL indication could double peak sales, if approved. Sym